PUBLISHER: Acute Market Reports | PRODUCT CODE: 1149169
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1149169
Allergy immunotherapy market accounted for a market value of US$ 1,953.1 Mn in 2020 and is projected to grow at a CAGR of 10.1% during the forecast period from 2022 to 2030. Allergy immunotherapy helps to prevent or minimize allergic reactions and provide long-term benefit to patients. This therapy helps to increase immunological tolerance and changes the course of disease due to which demand for immunotherapy is increasing globally.
SCIT is an effective therapy against allergic diseases as it delivers symptomatic relief by altering the effect of allergic reaction by focusing the basic mechanism of immunology. Thus, in 2020 SCIT identified as the largest allergy immunotherapy type that is preferred and adopted by most of the physicians. In addition to that, compared with conventional treatment the cost-effectiveness of SCIT is high and new molecules under trials will assist the overall growth of allergy immunotherapy.
The Asia Pacific is the fastest growing segment due to key driving factors such as rising prevalence & awareness related to allergic conditions, and industrialization & infrastructural development has increased air pollution in China & India. According to the World Health Organization (WHO), there has been significant growth in the prevalence of allergic rhinitis in Asia-Pacific within the last decade that has increased the economic burden. According to experts, the key factors responsible for sudden growth in allergic rhinitis is result of changing the environment, development in hygiene & reduced infections, and increasing cases of genetic complications.
This report also covers segments including data specific to major market trends, opportunities, drivers, and restraints, to gain precise information against global allergy immunotherapy market. The key market players analyzed in the report based on major attributes such as business strength, product portfolio, and important market strategies. The report also covers an attractive investment proposition based on the in-depth geographical research executed based on PESTEL analysis. The companies profiled in the report are Hollister Stier, Leti, WOLW Pharma, Aimmune Therapeutics, ALK-Abello A/S, Stallergenes Greer, Allergopharma, DBV Technologies, Allergy Therapeutics, Biomay AG, HAL Allergy Group, Circassia, and Merck KGaA, among others.
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Allergy Immunotherapy market are as follows:
Micro and macro environment factors that are currently influencing the Allergy Immunotherapy market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.